Serious adverse events: major bleeding · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: major bleeding compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events: major bleeding · Dialysis vascular access outcomes in AVF patients with ESKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious and non‐serious adverse events · people with asthma
1 finding from 1 review
Serious adverse events Up to 12 weeks' · Patients with acute low‐back pain
Paracetamol showed no clear difference in serious adverse events Up to 12 weeks' compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (Schröder 2006) · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate + infliximab changes serious adverse events (Schröder 2006) compared with infliximab alone (very low certainty).
1 finding from 1 review
All other (non‐serious) adverse events · people with chronic hepatitis C
1 finding from 1 review
Adverse events ‐ Serious adverse events · people with inhibitors
Summary of findings table ‐ Concizumab prophylaxis showed no clear difference in adverse events ‐ Serious adverse events compared with on‐demand therapy (low certainty).
1 finding from 1 review
Adverse events ‐ Serious adverse events · people without inhibitors
Summary of findings table ‐ Fitusiran prophylaxis showed no clear difference in adverse events ‐ Serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Adverse events considered non‐serious · adult patients after liver transplantation.
It is very uncertain whether prostaglandin changes adverse events considered non‐serious ( compared with placebo or standard care (very low certainty).
1 finding from 1 review
Serious adverse events within 6 monthsb · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Tixagevimab/cilgavimab showed no clear difference in serious adverse events within 6 monthsb compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events for all placebos · patients with mental health disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events: intussusception · children
Rotarix showed no clear difference in serious adverse events: intussusception compared with placebo (low certainty).
3 findings from 1 review
RR 0.72 [0.39, 1.32]
6 studies · 75540 participants
Low
RR 1.49 [0.06, 36.63]
5 studies · 17068 participants
Low
RR 1.42 [0.52, 3.87]
10 studies · 20773 participants
Low
Serious adverse events: intussusception · children
RotaTeq showed no clear difference in serious adverse events: intussusception compared with placebo (low certainty).
3 findings from 1 review
RR 0.69 [0.35, 1.38]
9 studies · 73925 participants
Low
RR 5.01 [0.24, 104.29]
2 studies · 4082 participants
Very low
RR 0.33 [0.01, 8.16]
2 studies · 7488 participants
Low
Serious adverse events: intussusception · children
Rotasiil showed no clear difference in serious adverse events: intussusception compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events: intussusception · children
It is very uncertain whether rotavac changes serious adverse events: intussusception compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (48 to 52 weeks) · Patients with quiescent ulcerative colitis
1 finding from 1 review
Serious adverse events: hospitalisation · adults with CVD
1 finding from 1 review
Intervention not reported
Serious adverse events during treatment · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes serious adverse events during treatment (very low certainty).
1 finding from 1 review
Serious ocular adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in serious ocular adverse events at 1 year compared with ranibizumab (moderate certainty).
1 finding from 1 review
RR 0.51 [0.05, 5.62]
1670 participants
Moderate
Serious ocular adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: anti‐VEGF treatment showed no clear difference in serious ocular adverse events at 1 year compared with control (moderate certainty).
1 finding from 1 review